Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant

Vaccine

Volumn 28, Issue 18, 2010, Pages 3152-3158

  Xue, Xiangyang ^a   Ding, Feng ^a   Zhang, Qingfeng ^a   Pan, Xuegong ^b   Qu, Li ^a   Pan, Weiqing ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Wanxing Biopharmaceuticals Co Ltd   (China)

Author keywords

Malaria vaccine; Montanide ISA720; PfCP 2.9 antigen; Potency assay

Indexed keywords

APICAL MEMBRANE ANTIGEN 1 MEROZOITE SURFACE PROTEIN 1 CHIMERIC VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MONTANIDE ISA 720; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STABILITY; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RABBIT; SEROCONVERSION; SHELF LIFE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DRUG STABILITY; DRUG STORAGE; EPITOPES; FEMALE; MALARIA VACCINES; MALE; MANNITOL; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; MICE; OLEIC ACIDS; PLASMODIUM FALCIPARUM; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTOZOAN PROTEINS; RABBITS; RECOMBINANT FUSION PROTEINS; TEMPERATURE; TIME FACTORS;

EID: 77949656640     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.054     Document Type: Article

References (21)

1. Gelb M.H. Drug discovery for malaria: a very challenging and timely endeavor. Current Opinion in Chemical Biology 11 August (4) (2007) 440-445
2. Greenwood B.M., Bojang K., Whitty C.J., and Targett G.A. Malaria. Lancet 365 April (9469) (2005) 1487-1498
3. Snow R.W., Guerra C.A., Noor A.M., Myint H.Y., and Hay S.I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434 March (7030) (2005) 214-217
4. Pan W., Huang D., Zhang Q., Qu L., Zhang D., Zhang X., et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. Journal of Immunology 172 May (10) (2004) 6167-6174
5. Zhang Q.F., Pan W.Q., Qu L., and Xue X.Y. Influence of deleting 9 amino acid residues at N-terminus on immunogenicity of a Plasmodium falciparum chimeric protein. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao Acta Biochimica et Biophysica Sinica 35 April (4) (2003) 345-349
6. Good M.F., Kaslow D.C., and Miller L.H. Pathways and strategies for developing a malaria blood-stage vaccine. Annual Review of Immunology 16 (1998) 57-87
7. O'Donnell R.A., de Koning-Ward T.F., Burt R.A., Bockarie M., Reeder J.C., Cowman A.F., et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. The Journal of Experimental Medicine 193 June (12) (2001) 1403-1412
8. Holder A.A., and Freeman R.R. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 294 November (5839) (1981) 361-364
9. Siddiqui W.A., Tam L.Q., Kramer K.J., Hui G.S., Case S.E., Yamaga K.M., et al. Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America 84 May (9) (1987) 3014-3018
10. Egan A.F., Burghaus P., Druilhe P., Holder A.A., and Riley E.M. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunology 21 March (3) (1999) 133-139
11. Kato K., Mayer D.C., Singh S., Reid M., and Miller L.H. Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx. Proceedings of the National Academy of Sciences of the United States of America 102 April (15) (2005) 5552-5557
12. Nair M., Hinds M.G., Coley A.M., Hodder A.N., Foley M., Anders R.F., et al. Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). Journal of Molecular Biology 322 September (4) (2002) 741-753
13. Lawrence G., Cheng Q.Q., Reed C., Taylor D., Stowers A., Cloonan N., et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 18 March (18) (2000) 1925-1931
14. Toledo H., Baly A., Castro O., Resik S., Laferte J., Rolo F., et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19 July (30) (2001) 4328-4336
15. Pattnaik P., Shakri A.R., Singh S., Goel S., Mukherjee P., and Chitnis C.E. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 25 January (5) (2007) 806-813
16. Saul A., Lawrence G., Allworth A., Elliott S., Anderson K., Rzepczyk C., et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23 April (23) (2005) 3076-3083
17. Hu J., Chen Z., Gu J., Wan M., Shen Q., Kieny M.P., et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults. PLoS ONE 3 4 (2008) e1952
18. Blackman M.J., Ling I.T., Nicholls S.C., and Holder A.A. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Molecular and Biochemical Parasitology 49 November (1) (1991) 29-33
19. Hodder A.N., Crewther P.E., Matthew M.L., Reid G.E., Moritz R.L., Simpson R.J., et al. The disulfide bond structure of Plasmodium apical membrane antigen-1. The Journal of Biological Chemistry 271 November (46) (1996) 29446-29452
20. Ljungström I P.H., Schichtherle M., Scherf A., and Wahlgen M. Methods in malaria research. Fourth ed. (2004), MR4/ATCC, Manassas, VA
21. Miles A.P., McClellan H.A., Rausch K.M., Zhu D., Whitmore M.D., Singh S., et al. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 23 March (19) (2005) 2530-2539